Research programme: cancer and diabetic foot ulcer therapeutics - Aurealis PharmaAlternative Names: AUP 100 series; AUP 16; AUP 500 series
Latest Information Update: 03 Nov 2016
At a glance
- Originator Aurealis Pharma
- Class Antibodies; Recombinant proteins
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
- Available For Licensing Yes - Cancer; Diabetic foot ulcer
Highest Development Phases
- Preclinical Diabetic foot ulcer
- Research Cancer